. 2018 Nov 10;4:617–627. doi: 10.1016/j.trci.2018.10.003

Table 3.

Regression coefficients between biomarkers, MTL volumes, and cognitive tests at baseline and difference in T-score at 2-year follow-up

Variable	CSF Ng	CSF BACE1	CSF Ng/BACE1	CSF t-tau	CSF Aβ_1–42	APOE-ε4 allele positivity
Variable	Biomarker and MTL measures entire sample (n = 57)/Aβ+ SCD and Aβ+ MCI (n = 30)
Amygdala	^∗/^∗	^∗/^∗	β = −.234^† / β = −420^†; P < .05 / P < .01	^∗/^∗	^§	^∗/^∗
Hippocampus	^∗/^∗	^∗/^∗	β = −.334^† / β = −.388^†; P < .01 / P < .05	^∗/^∗	^§	^∗/^∗
	Biomarkers and Baseline cognitive tests (N = 74)/Biomarkers and cognitive change at 2-year follow-up (n = 42)
MMSE	^∗/^∗	^∗/^∗	β = −.258^‡ / β = −.312; P < .05 / P < .05	^∗/^∗	^§	^∗/^∗
CERAD learning T-score	^∗/β = −.322; ^∗/ P < .05	^∗/^∗	β = −.266 / β = −.352; P < .05 / P < .05	^∗/β = −.413; ^∗/ P < .01	^§	^∗/^∗
CERAD recall T-score	^∗/^∗	^∗/^∗	β = −.312/^∗P < .05/^∗	^∗/^∗	^§	^∗/^∗
TMT-A T-score	^∗/^∗	^∗/^∗	β = −.238/^∗P < .05/^∗	^∗/^∗	^§	^∗/^∗
TMT-B T-score	^∗/^∗	^∗/^∗	^∗/^∗	^∗/^∗	^§	^∗/^∗

Abbreviations: CSF, cerebrospinal fluid; Ng, neurogranin; MTL, medial temporal lobe; BACE1, β-site amyloid precursor protein-cleaving enzyme 1; APOE-ε4+/−, apolipoprotein E 4 allele positive or negative; SCD, subjective cognitive decline; MCI, mild cognitive impairment; CERAD, the Consortium to Establish a Registry for Alzheimer's Disease word list test; MMSE, Mini Mental State Examination; TMT, trail-making test; MRI, magnetic resonance imaging.

^∗

Nonsignificant result.

^†

Model includes age, gender, and MRI scanner variant as covariate.

^‡

Model includes age as covariate.

^§

Not performed at baseline due to study design selection bias.